There's nothing new about the corporate quest to capitalize on growth in emerging economies. For GlaxoSmithKline (NYSE:GSK), which is increasing its stake in both in its Indian and Nigerian consumer health businesses, emerging economies provide an opportunity to boost otherwise stagnant revenue trends within its core pharmaceuticals business in the U.S. and Europe. In the following video, health care bureau chief Brenton Flynn runs through the Glaxo news and highlights some other big pharma players targeting emerging markets to spur growth going forward: Johnson & Johnson (NYSE:JNJ) and Abbott Laboratories (NYSE:ABT).
Motley Fool Returns
Discounted offers are only available to new members. Stock Advisor will renew at the then current list price. Stock Advisor list price is $199 per year.
Stock Advisor launched in February of 2002. Returns as of 10/22/2021.
Average returns of all recommendations since inception. Cost basis and return based on previous market day close.